Hermawan Adam, Putri Herwandhani
Laboratory of Macromolecular Engineering, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, 55281 Yogyakarta, Indonesia.
Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Sekip Utara II, 55281 Yogyakarta, Indonesia.
Asian Pac J Cancer Prev. 2025 Jan 1;26(1):279-292. doi: 10.31557/APJCP.2025.26.1.279.
OBJECTIVE: Programmed cell death-1 (PD-1, encoded by PDCD1) regulatory network participates in glioblastoma multiforme development. However, such a network in trastuzumab-resistant human epidermal growth factor receptor 2-positive (HER2+) breast cancer remains to be determined. Accordingly, this study was aimed to explore the PD-1 regulatory network responsible for the resistance of breast cancer cells to trastuzumab through a bioinformatics approach. METHODS: The study used data mining tools like cBioportal and OMIM to identify genes involved in the programmed cell death-1-trastuzumab resistance regulatory network. The network was further examined using various tools like WebGestalt, DAVID, STRING, Cytoscape, CytoHubba, GEPIA, TNMPlot, and ROCPlot. RESULTS: The PDCD1 regulatory network in trastuzumab-resistant HER2+ breast cancer is linked to Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), interleukin (IL)-10, protein tyrosine phosphatase receptor type C (PTPRC), and FCGR2B. These factors have a significant prognostic power in pathological complete response in breast cancer patients treated with trastuzumab. Infiltration of B cells, CD8+ cells, CD4+ cells, neutrophils, dendritic cells, macrophages, and regulatory T cells is directly correlated with PTR expression. CONCLUSION: The study identified four genes (CTLA4, IL10, PTPRC, and FCGR2B) that are linked to the regulatory network of PD-1 in trastuzumab-resistant HER2+ breast cancer cells. Further research is needed to develop the therapeutic target against trastuzumab resistance in HER2+ breast cancer.
目的:程序性细胞死亡蛋白1(PD-1,由PDCD1编码)调控网络参与多形性胶质母细胞瘤的发展。然而,曲妥珠单抗耐药的人表皮生长因子受体2阳性(HER2+)乳腺癌中的此类网络仍有待确定。因此,本研究旨在通过生物信息学方法探索负责乳腺癌细胞对曲妥珠单抗耐药的PD-1调控网络。 方法:本研究使用cBioportal和OMIM等数据挖掘工具来识别参与程序性细胞死亡蛋白1-曲妥珠单抗耐药调控网络的基因。使用WebGestalt、DAVID、STRING、Cytoscape、CytoHubba、GEPIA、TNMPlot和ROCPlot等各种工具对该网络进行进一步研究。 结果:曲妥珠单抗耐药的HER2+乳腺癌中的PDCD1调控网络与细胞毒性T淋巴细胞相关抗原4(CTLA-4)、白细胞介素(IL)-10、蛋白酪氨酸磷酸酶受体C型(PTPRC)和Fc段γ受体IIb(FCGR2B)相关。这些因素对接受曲妥珠单抗治疗的乳腺癌患者的病理完全缓解具有显著的预后预测能力。B细胞、CD8+细胞、CD4+细胞、中性粒细胞、树突状细胞、巨噬细胞和调节性T细胞的浸润与PTR表达直接相关。 结论:本研究确定了四个与曲妥珠单抗耐药的HER2+乳腺癌细胞中PD-1调控网络相关的基因(CTLA4、IL10、PTPRC和FCGR2B)。需要进一步研究以开发针对HER2+乳腺癌中曲妥珠单抗耐药的治疗靶点。
Asian Pac J Cancer Prev. 2025-1-1
Asian Pac J Cancer Prev. 2024-11-1
Health Technol Assess. 2006-9
Int J Clin Pharmacol Ther. 2018-2
Cochrane Database Syst Rev. 2018-2-6
J Immunother Cancer. 2022-1
Comput Struct Biotechnol J. 2021-7-18
Tzu Chi Med J. 2021-2-24